Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid

Fabiana Geraci1,2*, Paolo Ragonese3*, Maria Magdalena Barreca1, Emanuele Aliotta1, Maria Antonietta Mazzola3, Sabrina Realmuto3, Giulia Vazzoler3, Giovanni Savettieri3, Gabriella Sconzo1 and Giuseppe Salemi3

1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy, 2 Euro-Mediterranean Institute of Science and Technology, Palermo, Italy, 3 Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy

This study was designed based on the hypothesis that changes in both the levels and surface marker expression of extracellular vesicles (EVs) isolated from the cerebrospinal fluid (CSF) may be associated with the clinical form, disease activity, and severity of multiple sclerosis (MS). The analyzes were performed on subjects affected by MS or other neurological disorders. EVs, which were isolated by ultracentrifugation of CSF samples, were characterized by flow cytometry. A panel of fluorescent antibodies was used to identify the EV origin: CD4, CCR3, CCR5, CD19, and CD200, as well as isolectin IB4. The Mann-Whitney U-test and Kruskal-Wallis test were used for statistical analyzes. EVs isolated from the CSF were more abundant in patients with progressive MS and in those with a clinically isolated syndrome than in all the other groups examined. Furthermore, an important change in the number of EVs and in their surface marker expression occurred during active phases of MS [i.e., clinical relapses and the presence of enhancing lesions on magnetic resonance imaging (MRI)]. In particular, the number of CSF-EVs increased in patients affected by MS during clinical relapse; this finding was associated with a decrease in the number of CD19+/CD200+ (naïve B cells) EVs. These markers are expressed by immature and naïve B lymphocytes, and to the best of our knowledge, this double staining has never been associated with MS, but their reduction has been observed in patients with another type of Th1 cell-mediated autoimmune disease. In contrast, the presence of lesions in the brain and spine on gadolinium-enhanced MRI was associated with an increase in the numbers of CCR3+/CCR5+ (subset of CD8 memory T cells), CD4+/CCR3+ (Th2 cells), and CD4+/CCR5+ (Th1 cells) CSF-EVs. Two points are worth emphasizing: (i) the data obtained in this study confirm that CSF-EVs represent a potentially promising tool to...
IDENTIFICATION

Extracellular vesicles (EVs) are small double lipid membrane vesicles that are released by all cell types. These specialized structures were recently shown to be involved in intercellular communication via both autocrine and paracrine signaling. EVs represent a method for transferring information between cells (e.g., mRNA, miRNA, proteins, and lipids) located in close proximity or in distant sites through biological fluids (Raposo and Stoorvogel, 2013; Turturici et al., 2014; Gangoda et al., 2015; Ratajczak and Ratajczak, 2016). Indeed, EVs have been observed in almost all extracellular fluids [amniotic fluid, breast milk, urine, bronchoalveolar lavage fluid, cerebrospinal fluid (CSF), saliva, semen, and blood] (Witwer et al., 2013).

Two different types of EVs have been identified based on size and the mechanism of formation: exosomes, which are derived from the multivesicular endosomal cell compartment, and membrane-derived vesicles, which are formed by direct budding from the plasma membrane of the cell (Heijnen et al., 1999; Ratajczak et al., 2006; Candela et al., 2010; Morel et al., 2011; Théry, 2011; Abels and Breakfield, 2016). EVs contain a variety of cell surface receptors, signaling proteins, lipids, and nucleic acid, depending on the donor cell type. Therefore, the functions of EVs rely on the type of the parental cells. However, a selective enrichment of specific molecules has been observed, allowing EVs to have different properties and roles from their parental cells (Del Conde et al., 2005; Li et al., 2013). Several types of interactions between EVs and target cells have been identified. Indeed, the interplay may be mediated by ligand/receptor binding, or may be direct, followed by fusion or endocytosis (Turturici et al., 2014).

Several studies identified EVs in the CSF and described their roles in both physiological and pathological conditions, such as stroke, inflammatory neurodegenerative diseases and multiple sclerosis (MS) (Cherian et al., 2003; Horstman et al., 2007; Verderio et al., 2012). EVs have also been detected in blood samples from patients with MS, suggesting that they represent potential biomarkers that would enable clinicians to monitor disease onset and progression (Verderio et al., 2012; Sáenz-Cuesta et al., 2014a,b).

Multiple sclerosis is an autoimmune disorder of the central nervous system (CNS) that is associated with demyelination and neurodegeneration (Trapp and Nave, 2008). The clinical course of MS is highly heterogeneous, and according to traditional classifications, it ranges from a primary progressive (PPMS) form to the relapsing remitting (RRMS) form that is the most common clinical course (Compston and Coles, 2008) and has potentially different responses to available treatments. Another recently proposed classification subdivides MS courses into progressive (pMS) and relapsing (rMS), based on clinical and instrumental findings, with the understanding that the MS course is a dynamic process and that the subtype of classification may change over time (Lublin et al., 2014). The complex nature of MS poses challenges in diagnosis and monitoring disease activity, progression, and treatment responses. Therefore, extensive research has focused on identifying and validating molecular biomarkers that reflect its heterogeneous clinical course and determine the best treatment option for patients (Sáenz-Cuesta et al., 2014a).

Various studies conducted on the EVs isolated from both blood and CSF of subjects affected by MS have revealed an important role for these organelles in the pathogenesis of the disease (Barreca et al., 2017). EVs released by brain endothelial cells, leukocytes, or myeloid cells are involved in MS pathogenesis, inflammatory progression and lesion repair (Sáenz-Cuesta et al., 2014a). T cell activation might be the first step in the autoimmune reaction in the CNS induced by transendothelial leukocyte migration. As shown in the study by Minagar and colleagues, the concentration of endothelial cell-derived EVs depends on disease progression. In particular, these researchers showed that high levels of endothelial CD31-positive EVs were present in the plasma from patients with MS during disease exacerbation, whereas a reduction in the basal level of these EVs was observed during remission (Minagar et al., 2001). EVs released by platelets have also been detected in patients with RRMS (Shermata et al., 2008; Marcos-Ramiro et al., 2014).

Verderio and colleagues also reported the involvement of EVs in the inflammatory process. A higher myeloid IB4+ EV level was detected in the CSF from patients with RRMS than in healthy controls, and the EV concentration was correlated with gadolinium-positive lesions, a sign of active disease (Verderio et al., 2012).

However, the data on the involvement of EVs in the pathophysiology of MS only concern certain steps of the immunological response, and numerous aspects remain to be clarified. Thus, we planned an exploratory study to assess the expression of specific immunomarkers in EVs in the CSF from patients with MS. This project is expected to identify circulating vesicles in the CSF of patients with MS that can be used as a marker of the disease or of its active status. Therefore, the three major objectives of the study were to compare (1) the concentrations of EVs in the CSF from patients with MS who were diagnosed according to 2010 McDonald criteria (Polman et al., 2011) with subjects with other neurological disorders (ONDs); (2) the percentage of EVs in the CSF from patients with MS carrying different antigens due to their presumptive release by microglia, neurons, and different subtypes of lymphocytes, the main cells involved in MS pathogenesis, with subjects affected...
TABLE 1 | Surface markers used to identify different cell types in patients with MS.

| Marker  | Cell type                         | Reference                        |
|---------|-----------------------------------|----------------------------------|
| IB4     | Myeloid cells                     | Verderio et al., 2012            |
| CD4     | Th cells                          | Chitnis, 2007                    |
| CD4/CCR5| Th1                               | Bonecchi et al., 1998; Balashov et al., 1999; Zang et al., 2000 |
| CD4/CCR3| Th2                               | Uzawa et al., 2010               |
| CCR3/CCR5| A subset of CD8 memory T cells | Ferguson and Engelhard, 2010     |
| CD19    | B cells                           | Hauser, 2015                     |
| CD200   | Neurons, oligodendrocytes, and a subset of astrocytes | Koning et al., 2007; Koning et al., 2009; Valente et al., 2017 |
| CD19/CD200| Naïve B cells                  | Rasmussen et al., 2015          |

by OND; and (3) the concentration and percentage of CSF-EVs positive for specific surface markers (Table 1) isolated from patients with rMS using different parameters (i.e., clinical relapse, lesions on gadolinium-enhanced magnetic resonance imaging (MRI), disease duration, and steroid intake).

MATERIALS AND METHODS

Human Subjects

We included individuals affected by MS or OND that had a planned lumbar puncture for their diagnostic work-up during the period from February 2012 to September 2015. None of the patients had received any disease-modifying drug treatment 1 month prior to the lumbar puncture. For the purpose of the study, we collected 15–20 ml of CSF according to the international guidelines (Teunissen et al., 2009). Subjects were diagnosed with MS or clinically isolated demyelinating syndrome (CIS) according to the 2010 McDonald criteria (Polman et al., 2011). Following the publication of the 2013 Lublin criteria, the clinical course at the moment of the lumbar puncture was reclassified according to these new criteria as rMS and pMS (Lublin et al., 2014).

This research project was approved by the Ethics Committee of Palermo University, and all subjects provided written informed consent.

Magnetic Resonance Imaging Protocol

In the 15 days before the lumbar puncture, all patients with MS and CIS underwent MRI of the brain with a 1.5 T scanner Signa HDxt (GE Healthcare Medical System, Little Chalfont, United Kingdom) using standardized procedures. The maximum lag-time of 15 days between MRI and lumbar puncture was planned to minimize the risk that the data obtained from MRI and lumbar puncture represented two different phases of the disease, because the mean lifetime of a gadolinium-enhanced lesion is approximately 30 days (Guttmann et al., 1995; Ciccarelli et al., 1999). The neuroimaging protocol consisted of the following conventional sequences: FLAIR, T2, T1, and 2D contrast-enhanced T1-weighted SE/FSE. Cervical and dorsal spinal cord MRI scans were performed with the same 1.5 T scanner and the following conventional sequences: STIR, T2, T1, and 2D contrast-enhanced T1-weighted SE/FSE. Subjects with CIS were followed annually with visits and MRIs to evaluate their conversion to MS until November 2017. Controls affected by ONDs followed the diagnostic path planned according to their suspected illness.

Sample Preparation

Samples of 15–20 ml of CSF were collected in polypropylene tubes. Each sample was centrifuged at 432 × g for 15 min at room temperature. The supernatant was centrifuged at 1,730 × g for 15 min at room temperature and then frozen at −80°C until use.

Isolation of Extracellular Vesicles

The final supernatant was diluted in PBS to a final volume of 40 ml, and EVs were purified by ultracentrifugation at 105,000 × g for 90 min at 4°C. The pellet was resuspended in

TABLE 2 | Clinical and demographic features of the studied sample.

|                          | rMS     | pMS     | CIS     | OIND** | ONIND*** |
|--------------------------|---------|---------|---------|--------|----------|
| No. of patients          | 35      | 4       | 2       | 2      | 16       |
| Sex (female)             | 25      | 0       | 1       | 0      | 10       |
| Age                       | 34; 17–62 | 38; 27–44 | 35; 29–41 | 59; 52–66 | 53; 24–84 |
| EDSS                      | 2.0; 0.0–5.5 | 2.0; 0.0–6.0 | 1.5; 1.0–2.0 | NA     | NA       |
| Disease duration (months)* | 10; 1–360 | 17.5; 12–114 | 1; 1–1   | NR     | NR       |
| No. of subjects in relapse| 23      | 0       | 1       | NA     | NA       |
| No. of subjects taking steroids| 19      | 0       | 1       | NA     | NA       |
| No. of subjects with GAD+ lesions on MRI| 20      | 0       | 0       | NA     | NA       |

rMS, relapsing multiple sclerosis; pMS, progressive multiple sclerosis; CIS, clinically isolated syndrome; OIND, other inflammatory neurological disorder; ONIND, other non-inflammatory neurological disorder; EDSS, expanded disability status scale; GAD, gadolinium; MRI, magnetic resonance imaging; NR, not reported; NA, not applicable.

*The values are presented as medians; minima-maxima. **The two subjects with OIND were affected by myelitis. ***Four of the subjects with ONIND were diagnosed with a chronic cerebrovascular disease, four with normal pressure hydrocephalus, and one each with acute ischaemic stroke, benign intracranial hypertension, spastic paraparesis, parkinsonism, diabetic polyneuropathy, brain tumor outcomes, unspecified consciousness disorder, and conversion disorder.
10 ml of PBS and the sample was immediately frozen and stored at −80°C until use.

**Flow Cytometry Analysis**

The number of obtained EVs was determined by flow cytometry with a FACSCanTo instrument (BD Biosciences, Erembodegem, Belgium). One microliter of EVs was diluted in a fixed volume of 200 µl of filtered PBS (0.1 µm filter); all samples were analyzed by FACS for 30 s at medium flow rate. Gating was performed as described by Sáenz-Cuesta et al. (2014a). The event number corresponds to the number of EVs present in a specific volume of sample.

Samples were immunostained with a panel of fluorescent dye-conjugated antibodies, and the presence and concentration of specific markers were detected by flow cytometry to identify the cells that released EVs. In particular, we used the following markers in the FACS analysis: FITC-conjugated anti-CD19, PerCy-7-conjugated anti-CD200, Alexa Fluor 488-conjugated anti-CD4, APC-conjugated anti-CCR3, PerCpCY-5-conjugated anti-CCR5, and FITC-conjugated isoleucin IB4. Please see Table 1 for the cell types identified by these surface markers.

One microliter of EVs was diluted in a fixed volume (200 µl) of filtered FACS Buffer (2% fetal bovine serum in PBS) and incubated with 1 µl of the different antibodies for 45 min at 4°C in the dark. EVs were then washed by ultracentrifugation, resuspended in 200 µl of filtered PBS and analyzed by flow cytometry. The staining of the selected CDs/CCRs was analyzed in two different experimental sets, according to the fluorochromes used: (1) staining for CCR3, CCR5, and CD4, and (2) staining for CD19 and CD200. For IB4 staining, 1 µl of EVs was diluted in a fixed volume (200 µl) of filtered FACS Buffer (10% fetal bovine serum in PBS with Ca²⁺) and incubated with 2 µl of IB4 for 30 min at 4°C in the dark. EVs were then washed twice, resuspended in 200 µl of filtered PBS with Ca²⁺ and analyzed by flow cytometry.

Unstained controls were used to set photomultiplier tube voltages. Compensation was assessed using OneComp eBeads (eBioscience, San Diego, CA, United States), conjugated with the same labeled IgG isotype as the primary antibodies. IgG isotypes were also used as a negative control to determine the fluorescence background. All samples were analyzed by FACS for 30 s at medium flow rate.

All antibodies were purchased from eBioscience, and isoleucin IB4 was purchased from Life Technologies (Thermo Fisher Scientific, Waltham, MA, United States). The results obtained were analyzed with FlowJo V10.1 software (FlowJo LLC).

**Statistical Analysis**

Means or medians and the corresponding ranges were used to describe the distributions of all variables. Non-parametric tests were applied for statistical analyses; in particular, the Mann–Whitney U-test was used to compare two subgroups of patients, and the Kruskal–Wallis test was used to compare three or more subgroups of patients. SPSS software (SPSS, Inc., Chicago, IL, United States) was used for statistical analyses. The two-tailed alpha level was set to \( p < 0.05 \) to indicate a significant difference. The data were processed using GraphPad Prism software version 7.04 (GraphPad Software, La Jolla, CA, United States).

**RESULTS**

**Demographic and Clinical Characteristics of Patients**

We obtained EVs from the CSF of 39 subjects with MS, 2 subjects with CIS, and 18 subjects with OND. The 39 subjects with MS were classified according to the 2013 Lublin criteria as follows (Lublin et al., 2014): 35 with rMS (\( n = 35 \)), patients with pMS (\( n = 4 \)), patients with CIS (\( n = 2 \)), patients with OIND (\( n = 2 \)), and patients with ONIND (\( n = 16 \)). The Kruskal–Wallis statistical test was used to calculate the reported \( p \)-values (\( p = 0.49 \)). Individual dots indicate values for single donors.

(A) Quantitative flow cytometry analysis of EVs in human CSF collected from patients with rMS (\( n = 35 \)), patients with pMS (\( n = 4 \)), patients with CIS (\( n = 2 \)), patients with OIND (\( n = 2 \)), and patients with ONIND (\( n = 16 \)). The Mann–Whitney U-test was used to calculate the reported \( p \)-values (\( p = 0.02 \)). Individual dots indicate values for single donors.

Within the rMS subgroup, 19 patients had experienced at least two clinical attacks, 14 reported one clinical attack but, according to the 2010 McDonald criteria (Polman et al., 2011), were not yet considered to be affected by MS at the moment of enrolment. However, after 1 year of follow up, this patient was diagnosed with MS, and according to the new 2017 McDonald’s criteria
TABLE 3 | Demographic and clinical features of the population used to determine the fluorescence intensity of IB4+ CSF-EVs (EVs/ml).

| Patients | Controls |
|----------|----------|
|          | rMS      | pMS      | CIS     | OIND** | ONIND*** |
| No. of patients | 25 | 3 | 2 | 2 | 14 |
| Sex (female) | 17 | 0 | 1 | 1 | 9 |
| Age (years) | 34; 23–49 | 38; 38–44 | 35; 29–41 | 59; 52–66 | 50; 24–84 |
| EDSS | 2.0; 0.0–5.5 | 1.5; 1.0–6.0 | 1.5; 1.0–2.0 | NA | NA |
| Disease duration (months) | 14; 1–232 | 23; 12–114 | 1; 1–1 | NR | NR |
| No. of subjects in relapse | 17 | 0 | 1 | NA | NA |
| No. of subjects taking steroids | 14 | 0 | 1 | 0 | 0 |
| No. of subjects with GAD+ lesions on MRI | 16 | 0 | 0 | NA | NA |

CSF-EVs, cerebrospinal fluid extracellular vesicles; CIS, clinically isolated syndrome; rMS, relapsing multiple sclerosis; pMS, progressive multiple sclerosis; ONIND, other non-inflammatory neurological disorder; OIND, other inflammatory neurological disorder; ONIND, other non-inflammatory neurological disorder; ONIND, other inflammatory neurological disorder; EDSS, expanded disability status scale; GAD, gadolinium; MRI, magnetic resonance imaging; NR, not reported; NA, not applicable. “The values are presented as medians; minima-maxima. **The two subjects with ONIND were affected by myelitis. ***Four of the subjects with ONIND were diagnosed with normal pressure hydrocephalus, four with chronic cerebrovascular disorders, and one each with acute ischaemic stroke, spastic tetraparesis, benign intracranial hypertension, parkinsonism, diabetic polyneuropathy, and conversion disorder.

(Thompson et al., 2017), he was considered affected by MS since the beginning of symptom onset. The last patient was affected by a secondary progressive MS according to the traditional classification (Compston and Coles, 2008) but presented a relapse 16 days before the lumbar puncture. The 19 subjects affected by ONDs were split into two groups: 2 subjects with other inflammatory neurological disorders (OINDs), and 16 subjects with other non-inflammatory neurological disorders (ONINDs). Table 2 summarizes several demographic and clinical features of our sample.

The yield of EVs at the end of the isolation procedure did not permit us to perform all of the planned characterizations of EVs on the entire sample. Consequently, for each type of analysis, a table with the characteristics of each individual study population will be shown.

CSF-EV Characterization

Once isolated, CSF-EVs were characterized by FACS analysis and Nanoparticle Tracking Analysis (NTA) to confirm their identity. Flow cytometry assays showed that CSF-EVs vary in size but are ≤1 μm in diameter (Supplementary Figure S1A). We employed multi-parameter NTA to further define human CSF-EVs. First, we noted the presence of round vesicles displaying typical Brownian motion (Supplementary Figure S1C and Supplementary Movie S1B). The size of CSF-EVs isolated was similar as observed by transmission electron microscopy (Supplementary Figure S1D). To confirm that we have really isolated EVs, FACS analysis by using anti-Hsp70-FITC conjugated antibodies were carried out demonstrating its presence (Supplementary Figure S1E). Indeed, Hsp70 was considered for many years an exosome marker (Lancaster and Febbraio, 2005; Zhan et al., 2009) and more recently it has been demonstrated that this protein is also present within membrane vesicles (Barreca et al., 2017). In addition, since it has previously demonstrated that the acetylcholinesterase enzyme is enriched in EVs (Rieu et al., 2000; Candela et al., 2010), an acetylcholinesterase activity assay was performed to identify the presence of EVs in our samples (Supplementary Figure S1F). Furthermore, the flow cytometry analysis with Annexin-V, which binds externalized phosphatidylserine (PS), revealed that only a very small percentage of CSF-EVs displayed exposed PS on their surface (Supplementary Figure S1G). The specificity of the assay was confirmed by the result obtained in the absence of calcium. Indeed, under these conditions, the percentage of Annexin-V+ CSF-EVs was similar to CSF-EV autofluorescence. To the best of our knowledge, this study is the first to show that the majority of EVs isolated from CSF do not exhibit PS. In fact, almost all EVs contain PS (György et al., 2011), with some exceptions (Connor et al., 2010). Finally, the FACS analysis with pyronin Y, a dye that specifically labels RNA, showed the presence of this nucleic acid within the isolated CSF-EVs (Supplementary Figure S1H).

Although, due to the low amount of isolated material we could not follow all the ISEV suggestions to define EVs (i.e., western blot assays) (Lötvall et al., 2014), NTA, electron microscopy, Hsp70 and AChE presence, the results obtained after Triton X-100 treatment, PS exposure on the outer leaflet in a few samples, all together confirmed EV isolation.

Increased Concentration of CSF-EV in Patients with rMS in the Course of Clinical Relapse Compared to Patients With Stable MS

We assessed EV concentrations (EV/ml) in whole CSF samples from 59 subjects to determine whether patients with MS and patients with OND had different levels of EVs. Figure 1A shows the mean concentration/ml ± SD of CSF-EV in all examined groups. The analysis of variance and Kruskal–Wallis test did not show any significant difference among the groups (p = 0.49).

Subsequently, we evaluated the concentration of CSF-EVs in the rMS subgroup, according to different clinical and instrumental parameters (clinical relapse, lesions on
and OND displayed dissimilar biomarkers on their surface. This CSF of patients diagnosed with different clinical forms of MS we proceeded from the hypothesis that EVs present in the

Diseases Other Non-inflammatory Neurological

in Patients With MS and Patients With

Equal Percentage of EVs Positive for IB4

subgroups analyzed (data not shown).

FIGURE 2 | No differences in IB4+ CSF-EVs were observed among the examined samples. (A) Flow cytometry analysis of IB4+ CSF-EVs collected from patients with rMS (n = 25), patients with pMS (n = 3), patients with pMS (n = 2), patients with OND (n = 2), and patients with ONIND (n = 14). The Kruskal–Wallis statistical test was used to calculate the reported p-values (p = 0.83). Individual dots indicate values for single donors. (B) Quantitative flow cytometry analysis of CSF-EVs collected from patients with rMS in the clinically stable (n = 8) or acute (n = 17) phase of the disease. The Mann–Whitney U-test was used to calculate the reported p-values (p = 0.02). Individual dots indicate the values for single donors.


gadolinium-enhanced MRI, disease duration <9 months versus >9 months, and steroid treatment). Figure 1B shows the EV concentration in the CSF samples obtained from subjects during a clinical relapse and subjects who were in a phase of clinical stability (stable rMS). Subjects in the course of clinical relapse showed a significantly higher EV concentration than subjects in the clinically stable phase of the disease. The Mann–Whitney U-test showed a significant difference between groups, with p = 0.02.

We did not observe significant differences among the other subgroups analyzed (data not shown).

Equal Percentage of EVs Positive for IB4 in Patients With MS and Patients With Other Non-inflammatory Neurological Diseases

We proceeded from the hypothesis that EVs present in the CSF of patients diagnosed with different clinical forms of MS and OND displayed dissimilar biomarkers on their surface. This information might be relevant to monitor the progression of the disease and to discriminate between MS and OND. The evaluation of this hypothesis was conducted by monitoring biomarker levels present in circulating CSF-EVs from patients with different diseases.

A flow cytometry analysis was conducted on CSF-isolated EVs to determine the presence of IB4, a marker of myeloid origin. Table 3 summarizes demographic and clinical features of our sample. As experimental control we treated with Triton X-100 CSF-EV samples after its IB4 labeling. A reduction in MFI was observed, confirming that our particles are actually lipid structures and that IB4 has its target on membrane of isolated CSF-EVs (Supplementary Figure S2). Figure 2A shows the percentages ± SD of IB4+ EVs in the rMS, pMS, CIS, OIND, and ONIND groups. No statistically significant differences emerged from the comparison among the studied groups (p = 0.83), similar to the comparison among the other selected clinical and instrumental parameters in the rMS subgroups (data not shown). In contrast, after stratifying subjects with rMS according to clinical relapse, we observed a significant increase in the number of myeloid CSF-EVs in patients with stable rMS (Figure 2B).

Differences in the Expression of Surface Markers on CSF-EVs in Patients With rMS During the Course of Clinical Relapse and in the Presence of Lesions on Gadolinium-Enhanced MRI

Many studies have reported surface markers that identify Th1 and Th2 cells, as well as their relationship to MS and its mouse model, experimental autoimmune encephalomyelitis (EAE). For this reason, we determined the concentration of EVs positive for several CDs in the CSF of 25 patients with MS, 2 patients with CIS, and 13 controls using FACS analyzes; the demographic and clinical features are summarized in Table 4. Table 1 summarizes CDs selected for our analysis. Briefly, Th1 and Th2 subsets of CD4+ lymphocytes are characterized by the expression of some chemokine receptors. In particular, the chemokine receptor CCR5 is associated with the Th1 phenotype, whereas CCR3 is expressed preferentially on activated Th2 cells (Bonecchi et al., 1998; Scotet et al., 2001).

Supplementary Figures S3A–F shows the mean percentages ± SD of CD4+, CCR3+, CCR5+, CD4+/CCR3+, CD4+/CCR5+, and CCR3+/CCR5+ CSF-EVs in all examined groups. We did not observe statistically significant differences in the investigated markers among the five studied groups. Furthermore, after pooling the rMS subgroup according to some of the selected clinical and instrumental parameters (i.e., steroid intake and disease duration), similar concentrations of all markers were observed (data not shown). Additionally, after stratifying subjects with rMS according to clinical relapse, we did not obtain any statistically significant differences in the levels of these markers (Figures 3A–F). In contrast, in the presence of brain and spine lesions on gadolinium-enhanced MRI, regardless of the presence of clinical symptoms and signs of a relapse, subjects with rMS showed a statistically significant increase
TABLE 4 | Demographic and clinical features of the population used to determine the percentages of CSF-EVs positive for the CDs investigated.

|                      | Patients                  | Controls                   |
|----------------------|---------------------------|----------------------------|
|                      | rMS                       | pMS                        | CIS         | OIND* | ONIND*** |
| No. of patients      | 23                        | 2                          | 2           | 1     | 12       |
| Sex (female)         | 14                        | 0                          | 1           | 1     | 9        |
| Age                  | 35, 17, 62                | 41, 38, 44                 | 35; 29–41   | 66    | 50, 24, 84 |
| EDSS                 | 2.0; 0.0–4.5              | 3.75; 1.5–6.0              | 1.5; 1.0–2.0| NA    | NA       |
| Disease duration (months) | 17, 1, 360                | 17.5, 12, 23               | 1; 1–1      | NR    | NR       |
| No. of subjects in relapse | 18                      | 0                          | 1           | NA    | NA       |
| No. of subjects taking steroids | 15                     | 0                          | 1           | 0     | 0        |
| No. of subjects with GAD+ lesions on MRI | 13                  | 0                          | 0           | NA    | NA       |

CSF-EVs, cerebrospinal fluid extracellular vesicles; CDs, clusters of differentiation; CIS, clinically isolated syndrome; rMS, relapsing multiple sclerosis; pMS, progressive multiple sclerosis; OIND, other inflammatory neurological disorder; ONIND, other non-inflammatory neurological disorder; EDSS, expanded disability status scale; GAD, gadolinium; MRI, magnetic resonance imaging; NR, not reported; NA, not applicable. The values are presented as medians; minima-maxima. The subject with OIND was affected by myelitis. Three of the subjects with ONIND were diagnosed with chronic cerebrovascular disorders, two with normal pressure hydrocephalus, and one each with acute ischaemic stroke, benign intracranial hypertension, parkinsonism, spastic paraparesis, diabetic polyneuropathy, brain tumor outcomes, and conversion disorder.

FIGURE 3 | Differences in extracellular vesicles between patients with rMS in the course of a clinical relapse and stable phase. Flow cytometry analysis of extracellular vesicles stained for the selected CDs in CSF collected from patients with rMS in the clinically stable (n = 5) or acute (n = 18) phase of the disease. The Mann–Whitney U-test was used to calculate the reported p-values: (A) CD4 (p = 0.20), (B) CCR3 (p = 0.40), (C) CCR5 (p = 0.09), (D) CD4/CCR3 (p = 0.59), (E) CD4/CCR5 (p = 0.68), (F) CCR3/CCR5 (p = 0.86), (G) CD200 (p = 0.64), (H) CD19 (p = 0.48), and (I) CD19/CD200 (p = 0.03). Individual dots indicate the values for single donors.
FIGURE 4 | Differences in extracellular vesicles between patients with rMS in the course of a neuroradiological relapse and the stable phase. Flow cytometry analysis of extracellular vesicles stained for the selected CDs in CSF collected from patients with rMS in the neuroradiologically stable (n = 10) or active (n = 13) phase of the disease. The Mann–Whitney U-test was used to calculate the reported p-values: (A) CD4 (p = 0.52), (B) CCR3 (p = 0.004), (C) CCR5 (p = 0.042), (D) CD4/CCR3 (p = 0.018), (E) CD4/CCR5 (p = 0.004), (F) CCR3/CCR5 (p = 0.004). Individual dots indicate the values for single donors.

in the numbers of CCR3+ (p = 0.004), of CCR5+ (p = 0.042), CD4+/CCR3+ (p = 0.018), CD4+/CCR5+ (p = 0.004), and CC3+/CCR5+ (p = 0.004) CSF-EVs (Figures 4A–F). We also observed an increased number of CD4+/CCR5+ (Th1) CSF-EVs compared to CD4+/CCR3+ (Th2) CSF-EVs in patients with gadolinium-positive lesions (Figure 5).

Two other markers examined were CD19, one of the main membrane proteins of B lymphocytes, which is expressed in the maturation step (Stüve et al., 2014), and CD200, which is expressed on neurons, oligodendrocytes and on reactive astrocytes (Koning et al., 2009). Supplementary Figures S3G–I shows the mean percentages ± SD of CD200+, CD19+, and CD19+/CD200+ CSF-EVs in the rMS, pMS, CIS, OIND, and ONIND groups. We did not observe statistically significant differences in the comparisons among the five studied groups. Similarly, an evaluation of the markers in the rMS subgroups stratified according to steroid intake or disease duration showed similar concentrations (data not shown). Instead, we observed a statistically significant reduction in the number of CD19+/CD200+ CSF-EVs in subjects with in the course of a clinical relapse (p = 0.030) (Figure 3I), whereas we observed differences in these two markers between subjects with rMS stratified according to the presence of gadolinium-enhanced lesions, but these differences did not reach statistical significance (Figures 4G–I).

DISCUSSION

The aims of this work were to confirm the presence of circulating EVs in CSF, to identify some of the cells from which they originated, and to investigate the possible use of these CSF-EVs as biomarkers for both the diagnosis and determination of the active status of MS.

First, consistent with the literature, our data confirm the presence of EVs in CSF (Supplementary Figure S1). Moreover, the EV concentration is not a useful parameter for differentiating MS from ONDs (Figure 1A). This result is not surprising, as EVs are released by both inflammatory and non-inflammatory cells, which might be involved in different pathological conditions. A non-significant increase in the EV concentration was observed in patients with pMS and patients with CIS compared to patients with rMS (Figure 1A). In contrast, a statistically significant difference in the EV content was observed in patients with rMS stratified according to the two different clinical MS phases (i.e.,
FIGURE 5 | Levels of CD4+/CCR5+ CSF-EVs were increased in patients with rMS presenting with gadolinium-positive lesions. Flow cytometry analysis of CD4+/CCR3+ and CD4+/CCR5+ CSF-EVs in patients with rMS in the neuroradiologically stable (n = 10) or active (n = 13) phase of the disease. The Mann-Whitney U-test was used to calculate the reported p-values between gadolinium-positive patients with rMS (p = 0.13). Individual dots indicate the values for single donors.

FIGURE 6 | Significant differences in CSF-EV biomarkers among patients with rMS presenting different clinical and radiological statuses. Findings are summarized. The indicated biomarkers were different between comparison groups. The arrow preceding the name of each biomarker indicates an increase or decrease in the CSF-EV concentration in rMS groups, whereas the lack of an arrow indicates an invariant value. Solid arrows indicate statistically significant differences, and dotted arrows indicate non-significant differences.

stable or relapsing), with a higher concentration observed in relapsing subjects (Figure 1B). These results are consistent with findings reported by Minagar et al. (2001) and Verderio et al. (2012).

In the absence of specific cell-origin CSF-EV markers for MS, we decided to investigate the presence of markers derived from different cell types that could be involved in MS pathology (e.g., lymphocytes and myeloid cells) on EVs. One of the first examined markers was IB4, an isolectin that labels microglia (Figure 2A). Our results appear to be somewhat inconsistent with the findings reported by Verderio et al. (2012). Indeed, we observed a higher concentration of IB4+ CSF-EVs in subjects with rMS who were in the stable phase compared to subjects in the relapsing phase (Figure 2B). The differences observed between these two studies could be correlated to the lower size of our population, or to different settings of FACS.

Although the precise etiology of MS has not yet been thoroughly elucidated, many researchers postulate that it is an autoimmune disease characterized by the infiltration, accumulation and activation of myelin-specific T lymphocytes and macrophages in the CNS. In this inflammatory cascade, CD4+ T lymphocytes play a central role in the pathogenesis of MS, predominating in acute lesions (Chitnis, 2007), and chemokine receptors participate in their recruitment into the CNS. For this reason, we evaluated the presence of Th cell markers (i.e., CD4, CCR3, and CCR5) on circulating CSF-EVs. CCR3 and CCR5 are also expressed on foamy macrophages and activated microglia in chronic active MS plaques, as well as on astrocytes, particularly astrocytes forming processes around vessels and at the glia limitans. The two chemokine receptors, particularly CCR5, are also present on large numbers of infiltrating lymphocytes (Simpson et al., 2000; Trebst et al., 2001). Moreover, in C57BL6 mice, CCR5 knockout suppresses EAE (Gu et al., 2016). In our cohort of patients with rMS, a significant increase in CD4+/CCR5+ CSF-EVs was observed in the presence of gadolinium-positive lesions compared to gadolinium-negative lesions (Figure 4E). This
result was consistent with previous papers showing that Th1 lymphocytes are enriched in patients with MS and exhibit proinflammatory activity (Balashov et al., 1999; Zang et al., 2000). Furthermore, several studies have reported Th1 dominance over Th2 cells among peripheral blood lymphocytes and in the CSF of patients in the active phase of MS and in active demyelinating MS brain lesions (Balashov et al., 1999; Sorensen et al., 1999; Uzawa et al., 2010). Consistent with these data, we also observed an increased number of CD4+/CCR5+ CSF-EVs compared to CD4+/CCR3+ CSF-EVs in radiologically relapsing patients, although the increase was not statistically significant (Figure 5).

For decades, MS was thought to be a CD4+ T-cell mediated disease. However, interest has recently developed in the involvement of CD8+ T cells. Indeed, a large number of CD8+ T cells are present in CNS lesions (Babbe et al., 2000), and these cells appear to have a mixed functional phenotype (i.e., expression of cytotoxic/inflammatory, regulatory, and effector molecules) (Crawford et al., 2004; Baughman et al., 2011; Cunnusamy et al., 2014). In the present study, we observed a significantly higher level of CCR3+/CCR5+ EVs (Figure 4F). The coexpression of these two markers on the cell surface has been observed in a new subset of activated CD8 T cells (Ferguson and Engelhard, 2010), but the involvement of these cells in MS immunopathology has never been described.

In patients with MS, B cells are believed to cross the blood–brain barrier and undergo stimulation, antigen-driven affinity maturation and clonal expansion within the supportive CNS environment (Hauser, 2015), playing a major role in mediating tissue damage (Kuenz et al., 2008). The role of B cells is primarily to reduce MS activity induced by the administration of an anti-B lymphocyte monoclonal antibody (Baker et al., 2017). In our study, consistent with B cell involvement in MS, we observed a non-significant increase in the number of CD19+ EVs in both clinically and radiologically relapsing patients (Figures 3H, 4H).

Glia activation in patients with MS might be due to alterations in neuronal–glial and/or glial–glial crosstalk, and these alterations involve the CD200/CD200R system. The involvement of this pathway in MS pathology was reported by Valente et al. In fact, the authors showed that EAE is more severe in CD200−/− mice than in wild type mice (Valente et al., 2017). In contrast, the attenuated disease observed in EAE WldS mice was associated with robust constitutive expression of the CD200 molecule on neurons in the CNS compared with control mice (Chitnis et al., 2007). A reduction in the CD200 level was also observed on astrocytes in the center and rim of MS lesions (Koning et al., 2007), suggesting that CD200 might be involved in disease progression. Moreover, CD200R is expressed on cells of the myeloid lineage (Hock et al., 2000; Wright et al., 2000; Barclay et al., 2002) and is responsible for changing the phenotype of these cells from M1-like to M2-like (Lue et al., 2010). For this reason, CD200 appears to be an interesting marker. To the best of our knowledge, we are the first group to determine CD200 levels on the EV surface and show a decrease in clinically and radiologically relapsing subjects, even if the decrease was not statistically significant (Figures 3G, 4G). Due to their predicted involvement in glial activation and in the onset of clinical MS symptoms, CD200+ CSF-EVs must be examined in further investigations.

We have also observed significantly lower levels of CD19+/CD200+ CSF-EVs in our patients with MS during a clinically active phase than in patients in the stable phase (Figure 3I). CD19 and CD200 are both expressed on immature and naïve B lymphocytes (Rasmussen et al., 2015). This double staining has never been associated with MS, but a reduction in the number of CD19/CD200 B lymphocytes has recently been described in the acute phase of severe alopecia areata, a hair follicle-specific Th1 cell-mediated autoimmune disease (Gilhar and Kalish, 2006; Ma et al., 2017).

All of the discussed results are summarized in Figure 6. The present study provides evidence that the CSF-EV concentration is not a useful diagnostic parameter to differentiate MS from other neurological diseases. In contrast, certain markers selected to identify the cellular origin of CSF-EVs were differentially expressed during the relapsing phase of MS compared to the stable state of MS in the investigated rMS cohort. These differences were observed both during clinical relapse and in the presence of brain or spine lesions on gadolinium-enhanced MRI, suggesting that only some of the biological processes occurring during both plaque formation and the appearance of clinical symptoms are the same. This apparent “clino-radiological paradox” has been recently observed in a study showing that platelet-derived growth factor levels in the CSF predict a prolonged relapse-free period in patients with MS but not the lack of lesions on gadolinium-enhanced MRI (Stamponni Bassi et al., 2018).

The main weakness of our study could be the low number of included subjects, even if this number is similar to other studies of MS, and although our data must be confirmed in different and larger MS cohorts, CSF-EV observations might constitute a crucial prognostic tool that would be of benefit to further targeted projects and to the selection of the most appropriate therapy.

**ETHICS STATEMENT**

This study was approved by the Ethics Committee of the Medical School of the University of Palermo (Palermo 1). All subjects provided written informed consent in accordance with the Declaration of Helsinki.

**AUTHOR CONTRIBUTIONS**

FG, PR, GSc, GSav, and GSAl conceived and designed the experiments. FG, MB, and EA performed flow cytometry analyzes. PR, SR, MM, GV, GSav, and GSAl selected patients, performed lumbar puncture and collected and stored cerebrospinal fluid samples. PR, GSav, and GSAl analyzed the data. FG, PR, and GSAl wrote the manuscript. All authors have read and approved the final version of the manuscript.
FUNDING

This study was supported by funds from the University of Palermo for research activity.

ACKNOWLEDGMENTS

We thank M. Marchisio for the helpful discussions and suggestions. We thank G. Multhoff for the kind gift of cmHsp70.1 mAb.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2018.00418/full#supplementary-material

FIGURE S1 | Characterization of EVs isolated from CSF. (A) Flow cytometry analysis of isolated CSF-EVs. SSC, side scatter; FSC, forward scatter. For the size determination, polystyrene microspheres were used. (B) Representative graphs showing the size distributions and concentrations of CSF-EV as measured by nanoparticle tracking analysis (NTA) and (C) particles moving under Brownian motion. (D) Representative Transmission electron microscopic image of CSF-EVs. Scale bar represents 200 nm. (E) Flow cytometry histogram of CSF-EVs after anti-Hsp70-FITC conjugated antibodies staining. (F) Acetylcholinesterase assay activity. (G) Flow cytometry histogram of CSF-EVs after Annexin-V staining. (H) Pyronin Y labelling of CSF-EVs.

FIGURE S2 | CSF-EVs are detergent soluble. CSF-EVs stained with FITC-biotin measured before (blue) and after (green) treatment with 0.1% Triton X-100, showing that the detected events are detergent-soluble.

FIGURE S3 | Differences in extracellular vesicles between patients with multiple sclerosis and patients with other neurological disorders. Flow cytometry analysis of extracellular vesicles stained for the selected CDs in CSF collected from patients with nMS (n = 23), patients with pMS (n = 2), patients with CIS (n = 2), patients with ONIND (n = 1) and patients with ONIND (n = 2). The Kruskal–Wallis statistical test was used to calculate the reported p-values: (A) CD4 (p = 0.74), (B) CCR3 (p = 0.12), (C) CC(R) (p = 0.18), (D) CD4/CCR3 (p = 0.25), (E) CD4/CCR5 (p = 0.025), (F) CCR3/CCR6 (p = 0.93), (G) CD200 (p = 0.25), (H) CD19 (p = 0.25), and (I) CD19/CD200 (p = 0.25). Individual dots indicate the values for single donors.

TABLE S1 | Demographic and clinical features of patients with nMS at the moment of the lumbar puncture.

REFERENCES

Abels, E. R., and Breakefield, X. O. (2016). Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol. Neurobiol. 36, 301–312. doi: 10.1007/s10571-016-0366-z
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., et al. (2000). Clonal expansions of CD8 (+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micropipetting and single cell polymerase chain reaction. J. Exp. Med. 192, 393–404. doi: 10.1084/jem.192.3.393
Baker, D., Marta, M., Pryce, G., Giovannoni, G., and Schmierer, K. (2017). Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16, 41–50. doi: 10.1016/j.ebiom.2017.01.042
Balashov, K. E., Rottman, J. B., Weiner, H. L., and Hancock, W. W. (1999). CCR5(+) and CXCR4(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96, 6873–6878. doi: 10.1073/pnas.96.12.6873
Barclay, A. N., Wright, G. J., Brooke, G., and Brown, M. H. (2002). CD200 and membrane protein interactions in the control of myeloid cells. Adv. Exp. Med. Biol. 524, 144ñ151. doi: 10.1002/jcp.22111
Cherian, P., Hankey, G. J., Eikelboom, J. W., Thom, J., Baker, R. I., McQuillan, A., et al. (2003). Endothelial and platelet activation in acute ischemic stroke. J. Exp. Med. 192, 393ñ404. doi: 10.1084/jem.192.6.714
Gilhar, A., and Kalish, R. S. (2006). Alopecia areata: a tissue specific autoimmune disease. Autoimmun. Rev. 5, 64ñ69. doi: 10.1016/j.autrev.2005.07.001
Chitnis, T. (2007). The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 79, 43–72. doi: 10.1016/S0074-7746(07)79003-7
Chitnis, T., Immola, J., Wang, Y., Elyaman, W., Chawla, P., Sharuk, M., et al. (2007). Elevated neuronal expression of CD200 protects Wld5 mice from inflammation-mediated neurodegeneration. Am. J. Pathol. 170, 1695ñ1712. doi: 10.2353/ajpath.2007.060677
Cirecerelli, O., Giugni, E., Paolillo, A., Mainero, C., Gasperini, C., Bastianello, S., et al. (1999). Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur. J. Neurol. 6, 455–459.
Compton, A., and Coles, A. (2008). Multiple sclerosis. Lancet 372, 1502–1517. doi: 10.1016/S0140-6736(08)61620-7
Conn, D. E., Exner, T., Ma, D. D., and Joseph, J. E. (2010). The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb. Haemost. 103, 1044ñ1052. doi: 10.1160/TH09-09-0644
Crawford, M. P., Yan, S. X., Ortega, S. B., Mehta, R. S., Hewitt, R. E., Price, D. A., et al. (2004). High prevalence of autoantibodies in neuroantigen-specific CD8 T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103, 4222ñ4231. doi: 10.1182/blood-2003-11-4025
Cunnunasy, K., Baughman, E. J., Franco, J., Ortega, S. B., Sinha, S., Chaudhary, P., et al. (2014). Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. Clin. Immunol. 152, 115ñ126. doi: 10.1016/j.clim.2014.03.005
Del Conde, I., Shrimpton, C. N., Thiagarajan, P., and López, J. J. (2005). Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106, 1604ñ1611. doi: 10.1182/blood-2004-03-1095
Ferguson, A. R., and Engelhard, V. H. (2010). CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and co-express multiple chemokine receptors. J. Immunol. 184, 4079ñ4086. doi: 10.4049/jimmunol.0901903
Gangoda, L., Boukouris, S., Liem, M., Kalra, H., and Mathivanan, S. (2015). Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics 15, 260ñ271. doi: 10.1002/pmic.201400234
Gilhar, A., and Kalish, R. S. (2006). Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun. Rev. 5, 64ñ69. doi: 10.1016/j.autrev.2005.07.001
Gu, S. M., Park, M. H., Yoo, S. B., Oh, K. W., Son, D. J., et al. (2016). CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice. Oncotarget 7, 15382–15393. doi: 10.18632/oncotarget.8097
Guttmann, C. R., Ahn, S. S., Hsu, L., Kikinis, R., and Jolesz, F. A. (1993). The evolution of multiple sclerosis lesions on serial MR. Am. J. Neuroradiol. 14, 1481–1491
György, B., Szabó, T. G., Pásztió, M., Pál, Z., Misjak, P., Aradi, B., et al. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 67, 2667–2688. doi: 10.1007/s00018-011-0689-3
Hauser, S. L. (2015). The charcot lecture | beating MS: a story of B cells, with twists and turns. Mult. Scler. J. 21, 8–21. doi: 10.1177/1352458514561911
Heijnen, H. F., Schiel, A. E., Fijnheer, R., Geuze, H. J., and Sixma, J. J. (1999). Downregulation of Lue, L. F., Kuo, Y. M., Beach, T., and Walker, D. G. (2010). Microglia activation bodies and alpha-granules. Blood 94, 3791–3799.
Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, B., Lutterotti, A., Ehling, R., Gneiss, C., Haemmerle, M., Rainer, C., et al. (2014). Minimal experimental requirements for definition of extracellular vesicles. J. Extracellular Vesicles 3, 26913–26919. doi: 10.3402/jev.2014.26913
Horstman, L. L., Jy, W., Minagar, A., Bidot, C. J., Jimenez, J. J., Alexander, J. S., et al. (2007). Cell-derived microparticles and exosomes in neuroinflammatory disorders. Int. Rev. Neurosci. 28, 227–268. doi: 10.1556/2031.2007.00014
Koning, N., Swaab, D. F., Hoek, R. M., and Huitinga, I. (2009). Distribution of CCR1_/CCR5_ mononuclear phagocytes accumulate in the central nervous system of multiple sclerosis patients. Blood 98, 2568–2570. doi: 10.1182/blood.V98.8.2568
Kruyt, R. F., and van der Zee, M. A. (2011). Exosomes released during reticulocyte maturation bind to fibronectin via integrin alpha4beta1. Eur. J. Biochem. 268, 583–590.
Küenz, B., Lutterotti, A., Ehling, R., Gneiss, C., Haemmerle, M., Rainer, C., et al. (2008). Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 3:e2559. doi: 10.1371/journal.pone.0002559
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, T. L., Tani, M., Jensen, J., Pierce, V., Lucchinetti, C., Folcik, V. A., et al. (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807–815. doi: 10.1172/JCI51510
Lötvall, J., Hill, A. F., Hochberg, F., Buzás, E. I., Di Vizio, D., Gardiner, C., et al. (2011). CCR1 as a molecular target in CNS autoimmunity. Future Neurosci. 653–661. doi: 10.2217/bmm.14.9
Ma, X., Chen, S., Jin, W., and Gao, Y. (2017). Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. J. Neuroinflammation 14, 27–32. doi: 10.1186/s12974-018-1150-4
Mandessi, G., et al. (2018). Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. J. Neurol. 265, 159–263. doi: 10.1172/JNNL.2017.12.030
Mandolesi, G., et al. (2018). Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. J. Neurol. 265, 159–263. doi: 10.1172/JNNL.2017.12.030
Mantovani, A., Marini, M., italian Society for Extracellular Vesicles. J. Extravas. 5, 26913–26919. doi: 10.4161/rna.25281
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.
McDonald criteria.

multiple sclerosis and neuromyelitis optica. *BMC Neurol.* 10:113. doi: 10.1186/1471-2377-10-113

Valente, T., Serratosa, J., Perpiñá, U., Saura, J., and Solà, C. (2017). Alterations in CD200-CD200R1 system during EAE already manifest at presymptomatic stages. *Front. Cell. Neurosci.* 11:129. doi: 10.3389/fncel.2017.00129

Verderio, C., Muzio, L., Turola, E., Bergami, A., Novellino, L., Ruffini, F., et al. (2012). Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. *Ann. Neurol.* 72, 610–624. doi: 10.1002/ana.23627

Witwer, K. W., Buzás, E. I., Remis, L. T., Bora, A., Lässer, C., Lötvall, J., et al. (2013). Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J. Extracell. Vesicles* 2:20360. doi: 10.3402/jev.v2i0.20360

Wright, G. J., Puklavec, M. J., Willis, A. C., Hoek, R. M., Sedgwick, J. D., Brown, M. H., et al. (2000). Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. *Immunity* 13, 233–242. doi: 10.1016/S1074-7613(00)00023-6

Zang, Y. C., Samanta, A. K., Halder, J. B., Hong, J., Tejada-Simon, M. V., Rivera, V. M., et al. (2000). Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. *Brain* 123, 1874–1882.

Zhan, R., Leng, X., Liu, X., Wang, X., Gong, J., Yan, L., et al. (2009). Heat shock protein 70 is secreted from endothelial cells by a non-classical pathway involving exosomes. *Biochem. Biophys. Res. Commun.* 387, 229–233. doi: 10.1016/j.bbrc.2009.06.095

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Geraci, Ragonese, Barreca, Aliotta, Mazzola, Realmuto, Vazzoler, Savettieri, Sconzo and Salemi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.